Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Body, JJ; Marin, F; Kendler, DL; Zerbini, CAF; López-Romero, P; Möricke, R; Casado, E; Fahrleitner-Pammer, A; Stepan, JJ; Lespessailles, E; Minisola, S; Geusens, P.
Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial.
Osteoporos Int. 2020; 31(10):1935-1942
Doi: 10.1007/s00198-020-05463-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Fahrleitner-Pammer Astrid
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- FRAX® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those treated with teriparatide had a 60% lower risk of FRAX®-defined MOF compared with those treated with risedronate. The VERO trial was an active-controlled fracture endpoint clinical trial that enrolled postmenopausal women with severe osteoporosis. After 24 months, a 52% reduction in the hazard ratio (HR) of clinical fractures was reported in patients randomized to teriparatide compared with risedronate. We examined fracture results restricted to FRAX®-defined major osteoporotic fractures (MOF), which include clinical vertebral, hip, humerus, and forearm fractures. In total, 1360 postmenopausal women (mean age 72.1 years) were randomized to receive subcutaneous daily teriparatide (20 μg) or oral weekly risedronate (35 mg). Patient cumulative incidence of ≥ 1 FRAX®-defined MOF and of all clinical fractures were estimated by Kaplan-Meier analyses, and the comparison between treatments was based on the stratified log-rank test. Additionally, an extended Cox model was used to estimate HRs at different time points. Incidence fracture rates were estimated at each 6-month interval. After 24 months, 16 (2.6%) patients in the teriparatide group had ≥ 1 low trauma FRAX®-defined MOF compared with 40 patients (6.4%) in the risedronate group (HR 0.40; 95% CI 0.23-0.68; p = 0.001). Clinical vertebral and radius fractures were the most frequent FRAX®-defined MOF sites. The largest difference in incidence rates of both FRAX®-defined MOF and all clinical fractures between treatments occurred during the 6- to 12-month period. There was a statistically significant reduction in fractures between groups as early as 7 months for both categories of clinical fractures analyzed. In postmenopausal women with severe osteoporosis, treatment with teriparatide was more efficacious than risedronate, with a 60% lower risk of FRAX®-defined MOF during the 24-month treatment period. Fracture risk was statistically significantly reduced at 7 months of treatment. ClinicalTrials.gov Identifier: NCT01709110 EudraCT Number: 2012-000123-41.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Bone Density -
- Bone Density Conservation Agents - therapeutic use
- Double-Blind Method -
- Female -
- Humans -
- Osteoporosis, Postmenopausal - drug therapy
- Osteoporotic Fractures - epidemiology
- Osteoporotic Fractures - etiology
- Osteoporotic Fractures - prevention & control
- Risedronic Acid - therapeutic use
- Teriparatide - therapeutic use
- Find related publications in this database (Keywords)
- Bisphosphonates
- Fractures
- FRAX(R)
- Osteoporosis
- Risedronate
- Teriparatide